Orexo contemplates issuance of senior secured callable floating rate social bonds and announces a conditional tender offer for its existing bonds

The Tender Offer expires at the later of 16.00 CET on March 14, 2024, and the pricing date of the New Social Bonds, which will be announced by the Company in connection therewith, unless extended, shortened, re-opened, withdrawn, or terminated at the sole discretion of the Company (the "Expiration Date"). Settlement of the Tender Offer is expected to occur approximately ten business days after the Expiration Date. The Company will, in connection with the allocation of the New Social Bonds, consider, among other factors, whether or not the relevant investor seeking an allocation of the New Social Bonds has, prior to such allocation, validly tendered Existing Bonds pursuant to the Tender Offer, subject to the terms in the Tender Information Document.

The Tender Offer expires at the later of 16.00 CET on March 14, 2024, and the pricing date of the New Social Bonds, which will be announced by the Company in connection therewith, unless extended, shortened, re-opened, withdrawn, or terminated at the sole discretion of the Company (the "Expiration Date"). Settlement of the Tender Offer is expected to occur approximately ten business days after the Expiration Date. The Company will, in connection with the allocation of the New Social Bonds, consider, among other factors, whether or not the relevant investor seeking an allocation of the New Social Bonds has, prior to such allocation, validly tendered Existing Bonds pursuant to the Tender Offer, subject to the terms in the Tender Information Document.

Conditional upon a successful issue of the New Social Bonds (including receipt of proceeds), Orexo further intends to exercise its right to make an early redemption of the Existing Bonds not being tendered in the Tender Offer in accordance with the terms and conditions of the Existing Bonds. The Existing Bonds will in such an early redemption be redeemed at a price equal to 100.750 per cent of the nominal amount plus any accrued and unpaid interest. 

Gernandt & Danielsson Advokatbyrå KB has been appointed as legal counsel in connection with the contemplated issuance of the New Social Bonds and the Tender Offer.

For further information please contact:

Nikolaj Sørensen, President and CEO
Fredrik Järrsten, EVP and CFO
Lena Wange, IR & Communications Director
Tel: +46 (0)18 780 88 00
E-mail: ir@orexo.com 

About Orexo

Orexo is a Swedish pharmaceutical company with over 25 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2023 amounted to SEK 639 million, and the number of employees to 116. Orexo is listed on Nasdaq Stockholm's main list and is available as an ADR on OTCQX (ORXOY) in the US.

For more information about Orexo please visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube.

The information was sent for publication, through the agency of the contact person set out above, on March 8, 2024,
at 8.10 CET.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/orexo/r/orexo-contemplates-issuance-of-senior-secured-callable-floating-rate-social-bonds-and-announces-a-co,c3942854

The following files are available for download:

 

View original content:https://www.prnewswire.co.uk/news-releases/orexo-contemplates-issuance-of-senior-secured-callable-floating-rate-social-bonds-and-announces-a-conditional-tender-offer-for-its-existing-bonds-302083868.html